The product can not be sold in a country where it is illegal.

The best way to purchase ADB-F

Specification
Product Name: ADB-F
IUPAC Name: N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
Other Names: ADB-FUBINACA
Cas Number: 1445583-51-6
Molecular Formula: C21H23FN4O2
Molar Mass: 382.43 g/mol
Effect: stimulant, psychedelic
Purity of the substance: 99.9%
Physical properties: Crystals, powder
100g
$630
200g
$850
300g
$970
500g
$1500
2000g
$3700
1000g
$2300
5000g
$6500
10000g
$11000
The best way to purchase ADB-F
In Stock
Delivery:

- FREE shipping, 6-7 days delivery time
- Inner sending exist.
The main payment option is Bitcoin. As extra ways WU, MG.
We alwayse provide FREE samples of Top products with the main order.

Loyalty program exist, second order will be - 5%OFF

Safely work only with us! We provide - re-shipment guarantees.

Here you'll discover unused lawful items of immaculate quality.

Some time recently purchase if you don't mind make beyond any doubt that the items beneath your curiously are lawful in your country.

We do not offer a pharmaceutical items or beneath control items.

The best way to get legal high with us to buy ADB-F for sale

ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration. The (S)-enantiomer of ADB-FUBINACA is described in a 2009 Pfizer patent[4]. It has been reported to be a potent agonist of the CB1 receptor and the CB2 receptor with EC50 values of 1.2 nM and 3.5 nM, respectively. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135.

ADB-F is a drug identified in synthetic cannabis blends in Japan in 2013.

This product is the (S)-enantiomer of ADB-FUBINACA, a designer drug identified in synthetic cannabis blends in Japan in 2013. ADB-F has been reported to be a potent agonist of the CB1 receptor and the CB2 receptor, with EC50 values of 1.2 nM and 3.5 nM, respectively.

ADB-FUBINACA, also known as 5-(2-aminopropyl)-1-(4-fluorobenzyl)-N-(2-phenylpropylamino) indazole or 5-[(S)-1-(4-fluorobenzyl)-1H-indazol-3-yl]-N-[(S)-1-(4-phenylazetidin-3-yl)propyl] carboxamide, is an indazole cannabinoid derived from indazole by attachment of a phenethylamine side chain. ADB-FUBINACA is the product of rational drug design and features a replacement at the carbonyl that attaches FUBINACA to serotonin and dopamine.

ADB-F, also known as 5-(2-aminopropyl)-1-(4-fluorobenzyl)-N-(2-phenylpropylamino) indazole or 5-[(S)-1-(4-fluorobenzyl)-1H-indazol-3-yl]-N-[(S)-1-(4-phenylazetidin-3-yl)propyl] carboxamide, is an indazole cannabinoid derived from indazole by attachment of a phenethylamine side chain. ADB-FUBINAC can be used for antiemetic or analgesic purposes.


Looking for online research chemicals ADB-F vendor USA


ADB-FUBINACA is an indazole cannabinoid derived from indazole by attachment of a phenethylamine side chain.

ADB-FUBINACA is a drug made of an indazole cannabinoid and a phenethylamine side chain.

ADB-FUBINACA is an indazole carboxamide derived from serotonin and dopamine. ADB-FUBINACA's wide availability on sale and increased use may reflect exposure risks similar to those of CB-13 and THJ-2201."

ADB-FUBINACA is a potent and selective CB1 receptor agonist.

ADB-FUBINACA is a synthetic cannabinoid drug produced by various underground laboratories in China and elsewhere. Unlike other cannabinoids that are very potent, ADB-FUBINACA is relatively weak.

ADB-FUBINACA (1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) is a synthetic cannabinoid that acts as a potent agonist for the CB1 and CB2 cannabinoid receptors. It was first identified in Japan in 2013.

ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. It was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration.

The enantiomers ADB-FUBINACA and SDB-001 were first identified in synthetic cannabis blends in Japan in 2013. They are now the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration.

ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration. The (S)-enantiomer of ADB-FUBINACA is described in a 2009 Pfizer patent. It has been reported to be a potent agonist of the CB1 receptor and the CB2 receptor with EC50 values of 1.2 nM and 3.5 nM, respectively. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135.


1kg $1590

200g $590

1kg $1690

1kg $1890

1kg $1890

out of stock

100g $550

500g $1390

500g $1199

1kg $1590

100g $390